Headaches in the Different Phases of Relapsing-Remitting Multiple Sclerosis A Tendency for Stabbing Headaches During Relapses

被引:28
|
作者
Ergun, Ufuk [1 ]
Ozer, Goekhan [1 ]
Sekercan, Sine [2 ]
Artan, Elif [2 ]
Kudiaki, Cigdem [2 ]
Ucler, Serap [1 ]
Coskun, Ozlem [1 ]
Inan, Levent [1 ]
机构
[1] Ankara Educ & Res Hosp, Minist Hlth, Dept Neurol, Ankara, Turkey
[2] Mersin Univ, Dept Psychol, Mersin, Turkey
关键词
multiple sclerosis; headache; stabbing headache; interferon; BECK DEPRESSION INVENTORY;
D O I
10.1097/NRL.0b013e3181906fc9
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Introduction: Primary headaches are known to be associated with multiple sclerosis. We aimed to determine headaches using ICHD-II in different phases of relapsing-remitting multiple sclerosis, and the correlation between headaches and several features of the disease. Results: Migraine (41.2%) and tension-type headaches (20.6%) were the most common headaches in remission, and primary stabbing headache (PSH) (27.8%) was common in the relapsing phase. Although headaches seemed to occur independently of disease duration, extended disability status scale, beck depression inventory scores, and treatments, the total number of headaches was correlated with periventricular lesions (P = 0.03) and tension-type headaches were correlated with spinal lesions in remission (P = 0.02). Total number of headaches was correlated with brain stern lesions ill the relapsing phase (P = 0.05). Conclusion: The high frequency of PSHs in relapse was notable, and, to the best of our knowledge, PSH was not reported in relapsing-remitting multiple sclerosis before. Further studies with larger samples are recommended.
引用
收藏
页码:212 / 216
页数:5
相关论文
共 50 条
  • [41] Daclizumab for the treatment of relapsing-remitting multiple sclerosis
    Herwerth, Marina
    Hemmer, Bernhard
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2017, 17 (06) : 747 - 753
  • [42] Ocrelizumab for the treatment of relapsing-remitting multiple sclerosis
    Menge, Til
    Dubey, Divyanshu
    Warnke, Clemens
    Hartung, Hans-Peter
    Stuve, Olaf
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2016, 16 (10) : 1131 - 1139
  • [43] Development of laquinimod for relapsing-remitting multiple sclerosis
    Jeffery, Douglas R.
    FUTURE NEUROLOGY, 2008, 3 (06) : 641 - 648
  • [44] Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis
    Hersh, Carrie M.
    Cohen, Jeffrey A.
    IMMUNOTHERAPY, 2014, 6 (03) : 249 - 259
  • [45] Alemtuzumab in the treatment of relapsing-remitting multiple sclerosis
    Fox, Edward J.
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2010, 10 (12) : 1789 - 1797
  • [46] Natalizumab in spinal relapsing-remitting multiple sclerosis
    Zecca, C.
    Kamm, C.
    Riccitelli, G. C.
    Heldner, M.
    Caporro, M.
    Gobbi, C.
    EUROPEAN JOURNAL OF NEUROLOGY, 2014, 21 : 457 - 457
  • [47] Intravenous immunoglobulin in relapsing-remitting multiple sclerosis
    Achiron, A
    Barak, Y
    SarovaPinhas, I
    Achiron, R
    Gabbay, U
    Rotstein, Z
    Noy, S
    INTRAVENOUS IMMUNOGLOBULIN: RESEARCH AND THERAPY, 1996, : 289 - 293
  • [48] Cognitive Impairment In Relapsing-Remitting Multiple Sclerosis
    Topcular, Baris
    Ozcan, M. Emin
    Kurt, Elif
    Kuscu, Demet Yandim
    Icen, Nilufer Kale
    Sutlas, Pakize Nevin
    Kirbas, Dursun
    Bingol, Ayhan
    NOROPSIKIYATRI ARSIVI-ARCHIVES OF NEUROPSYCHIATRY, 2012, 49 (03): : 178 - 182
  • [49] Oral fingolimod for relapsing-remitting multiple sclerosis
    Doggrell, Sheila A.
    EXPERT OPINION ON PHARMACOTHERAPY, 2010, 11 (10) : 1777 - 1781
  • [50] Thalamic neurodegeneration in relapsing-remitting multiple sclerosis
    Wylezinska, M
    Cifelli, A
    Jezzard, P
    Palace, J
    Alecci, M
    Matthews, PM
    NEUROLOGY, 2003, 60 (12) : 1949 - 1954